Collaborative studies among veterinarians and oncology researchers are yielding new insights into NHL, inspiring innovative ...

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

Five diagnosed prevalent cases will grow to over 714,000. Diagnosed incident cases of B-cell non-Hodgkin’s lymphoma (B-cell ...

Hodgkin's lymphoma and acute lymphoblastic leukemia—two types of cancer that affect blood cells—do not respond adequately to treatment with CAR-T cells. The therapy involves harvesting the patient's ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

Future research into non-Hodgkin lymphoma treatments needs to explore long-term outcomes and a better understanding biologic ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...